Timentin

Држава: Нови Зеланд

Језик: Енглески

Извор: Medsafe (Medicines Safety Authority)

Активни састојак:

Potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage);  ; Ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage)

Доступно од:

GlaxoSmithKline NZ Limited

INN (Међународно име):

Potassium clavulanate 128 mg (= clavulanic acid 100 mg (based on 82% potency +5% overage))

Фармацеутски облик:

Powder for injection

Састав:

Active: Potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage)   Ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage)

Јединице у пакету:

Vial, glass, 3.1g, 1 dose unit

Класа:

Prescription

Тип рецептора:

Prescription

Произведен од:

SmithKline Beecham Pharmaceuticals Ltd

Терапеутске индикације:

The treatment of infections caused by susceptible strains of organisms in the conditions listed below: - Septicaemia (including bacteraemia) - Lower Respiratory Tract Infections - Bone and Joint Infections - Skin and Skin Structure Infections - Urinary Tract Infections - Gynaecological Infections - Surgical Prophylaxis Appropriate culture and susceptibility tests should be performed in order to isolate and identify organisms causing infection and to determine their susceptibility to TIMENTIN. Susceptibility to TIMENTIN will vary with geography and time and local succeptibility data should be consulted where available. In certain infections, when the causative organisms are unknown, TIMENTIN may be administered in conjunction with an aminoglycoside as initial therapy. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. May be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal hysterectomy, abdominal surgery, and colorectal surgery when there is a significant risk of postoperative infection or where occurrence of postoperative infection is considered to be especially serious.

Резиме производа:

Package - Contents - Shelf Life: Vial, glass, 3.1g - 1 dose units - 18 months from date of manufacture stored at or below 25°C

Датум одобрења:

1986-02-27

Информативни летак

1
TIMENTIN
® INJECTION
TICARCILLIN DISODIUM/POTASSIUM CLAVULANATE
WHAT IS IN THIS LEAFLET
This leaflet answers some
common questions about
TIMENTIN. It does not
contain all the available
information. It does not take
the place of talking to your
doctor or pharmacist.
Please read this leaflet before
you start using TIMENTIN.
All medicines have risks and
benefits. Your doctor has
weighed the expected benefits
against possible risks of you
using TIMENTIN. If you have
any concerns about using this
medicine, ask your doctor or
pharmacist.
Keep this leaflet with the
medicine. You may need to
read it again.
WHAT TIMENTIN IS
USED FOR
TIMENTIN is an antibiotic
used to treat infections in
different parts of the body
caused by bacteria.
TIMENTIN will not work
against infections caused by
viruses such as colds or the flu.
TIMENTIN is also used to
prevent infection from major
surgery.
TIMENTIN is an antibiotic
that belongs to a group of
medicines called penicillins.
These antibiotics work by
killing the bacteria that are
causing your infection.
This medicine is available only
with a doctor’s prescription.
BEFORE YOU TAKE
TIMENTIN
_DO NOT TAKE TIMENTIN _
_IF: _

you have an allergy to
TIMENTIN, other
penicillins or any of the
ingredients listed at the end
of this leaflet.
Some of the symptoms of
an allergic reaction may
include skin rash, itching,
difficulty breathing.

you have had an allergic
reaction to cephalosporins
(another type of antibiotic).
You may have an increased
chance of being allergic to
TIMENTIN if you are
allergic to cephalosporins.

the packaging is torn or
shows signs of tampering.

the expiry date (EXP)
printed on the pack has
passed.
If you take this medicine
after the expiry date has
passed, it may not work.
If you are not sure whether you
should start using TIMENTIN,
contact your doctor.
Do not give this medicine to
anyone else. Your doctor has
prescribed it specifically for
you and your condition.
_BEFORE YOU START TO TAKE _
_TIMENTIN _
TELL YOUR DOCTOR IF:

you have any allergies to

Карактеристике производа

1
NEW ZEALAND DATA SHEET
TIMENTIN
® INJECTION POWDER
_TICARCILLIN DISODIUM/POTASSIUM CLAVULANATE _
_ _
PRESENTATION
TIMENTIN 3.1g vials: Each vial contains sterile ticarcillin disodium
equivalent to 3g ticarcillin and sterile
potassium clavulanate equivalent to 0.1g clavulanic acid.
TIMENTIN is supplied as a white to pale yellow powder for
reconstitution.
TIMENTIN is very soluble in water; its solubility being greater than
600mg/mL. The reconstituted solution
is clear, colourless or pale yellow, having a pH of 5.5 to 7.5.
The theoretical sodium content is 4.8mEq (111mg) per gram of TIMENTIN.
+
INDICATIONS
TIMENTIN is indicated in the treatment of infections caused by
susceptible strains of organisms in the
conditions listed below:

Septicaemia (including bacteraemia)

Lower Respiratory Tract Infections

Bone and Joint Infections

Skin and Skin Structure Infections

Urinary Tract Infections

Gynaecological Infections

Surgical Prophylaxis
Appropriate culture and susceptibility tests should be performed in
order to isolate and identify organisms
causing infection and to determine their susceptibility to TIMENTIN.
Susceptibility to TIMENTIN will vary
with geography and time and local susceptibility data should be
consulted where available (see Further
Information, Pharmacodynamic properties).
In certain infections, when the causative organisms are unknown,
TIMENTIN may be administered in
conjunction with an aminoglycoside as initial therapy. As soon as
results of culture and susceptibility tests
become available, antimicrobial therapy should be adjusted as
indicated.
TIMENTIN may be administered perioperatively (preoperatively,
intraoperatively and postoperatively) to
patients undergoing vaginal hysterectomy, abdominal surgery, and
colorectal surgery when there is a
significant risk of postoperative infection or where occurrence of
postoperative infection is considered to
be especially serious.
2
In patients undergoing caesarean section, intraoperative (after
clamping the umbilical cord) and
po